REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase II trial

ANNÉE

2019

AUTEURS

Samalin E, Turpin A, Khemissa F, Zaanan A, Ben Abdelghani M, Senellart H, Gilabert M, Evesque L, Dahan L, Sefrioui D, Bouche O, De La Fouchadiere C, Hennequin A, Monard L, Gourgou S, Lopez A

CONGRÈS/REVUE

ESMO GI

LIEN PUBLICATIONS ASSOCIÉES